Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling

Mosunetuzumab, a T-cell dependent bispecific antibody that binds CD3 and CD20 to drive T-cell mediated B-cell killing, is currently being tested in non-Hodgkin lymphoma. However, potent immune stimulation with T-cell directed therapies poses the risk of cytokine release syndrome, potentially limitin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosseini, Iraj, Gadkar, Kapil, Stefanich, Eric, Li, Chi-Chung, Sun, Liping L., Chu, Yu-Waye, Ramanujan, Saroja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455723/
https://www.ncbi.nlm.nih.gov/pubmed/32859946
http://dx.doi.org/10.1038/s41540-020-00145-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455723/
https://www.ncbi.nlm.nih.gov/pubmed/32859946
http://dx.doi.org/10.1038/s41540-020-00145-7

Ejemplares similares